Gain Therapeutics (GANX) Expected to Announce Earnings on Tuesday

Gain Therapeutics (NASDAQ:GANX) is expected to be releasing its Q1 2025 earnings data before the market opens on Tuesday, May 13th. Analysts expect Gain Therapeutics to post earnings of ($0.16) per share for the quarter.

Gain Therapeutics (NASDAQ:GANX) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.07. On average, analysts expect Gain Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Gain Therapeutics Stock Performance

NASDAQ:GANX opened at $1.94 on Friday. The stock has a market cap of $57.09 million, a P/E ratio of -1.76 and a beta of 0.17. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04. The business’s 50-day moving average price is $1.94 and its two-hundred day moving average price is $2.03. Gain Therapeutics has a twelve month low of $0.89 and a twelve month high of $3.19.

Analyst Ratings Changes

Several equities analysts recently commented on GANX shares. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of Gain Therapeutics in a report on Monday, March 17th. Scotiabank assumed coverage on Gain Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $12.00 price objective on the stock. Finally, Chardan Capital restated a “buy” rating and set a $6.00 target price on shares of Gain Therapeutics in a report on Friday, March 28th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $8.20.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.